The team emphasized that the study — using only one type of MS mouse model — is not enough to draw conclusions about the treatment’s effectiveness. Before proceeding to human trials, the compound must be examined in other MS models.
Protamine is also not an optimal drug to advance as a myelin regeneration treatment. While it is used clinically, it has been linked to severe side effects, including high blood pressure and catastrophic constriction of lung blood vessels.
Since the compound was not effective when administered intranasally in adult mice, the team also underscored the need for remyelination-boosting drugs that can easily pass into the brain.
Researchers believe that the search for such compounds will, however, be easier by using protamine as a blueprint.
“We found that protamine effectively promoted developmental myelination in mouse pups and remyelination in a cuprizone-induced demyelination model. This study thus suggested the possibility that development of CSPG-neutralizing agents is a promising strategy for treating the developmental retardation of myelination and demyelinating diseases,” the team concluded.